The US FDA has ordered BioNTech to immediately halt its Phase I/II trial of BNT165e, a malaria vaccine candidate, pending ...
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.
Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics ...
The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...
The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced ...
CAMBRIDGE, MASS., March 13, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune ...
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...
today announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial in ALS. This pivotal step marks a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results